Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer’s disease Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer’s; 24-week […]
GlaxoSmithKline is succeeding with newly launched products and strong R&D flow while struggling with U.S. pricing and competitive pressures.
The industry’s patent cliffs have become less steep, but the Affordable Care Act will give pharma new challenges.
The last few months have seen two major shifts for Bristol-Myers Squibb – out of diabetes and into immuno-oncologics.
AstraZeneca’s efforts to rebuild its pipeline and invest in its growth platforms attracted Pfizer’s notice, with an unsolicited bid of acquisition.
Bolstered by company-record sales, innovative blockbuster products, successful M&A activity, and a pipeline of medicines with breakaway potential, Amgen becomes the first biotech entity to be recognized by Med Ad News as its Company of the Year.